BUILDING A TEAM OF PASSIONATE VISIONARIES TO BRING NEW HOPE TO MILLIONS
We’re using the world’s leading boron-based discovery platform to discover and develop medicines in innovative and imaginative new ways. By utilizing boron’s unique characteristics to access novel binding sites, we’re looking to advance therapeutics in areas where there are critical gaps that limit current treatment options. Our goal is to make impactful medicines that can truly change the course of disease—and the lives of patients and their loved ones.
Leadership team
Leadership team
Eric Easom
Co-founder, President, CEO, and Chair
Josh Eizen
Chief Legal and Operating Officer
Lucy Day
Chief Financial Officer
Sanjay Chanda, PhD
Chief Development Officer
Vince Hernandez
Head of Research
Cameron Trenor, MD
Chief Medical Officer
Board of directors
Eric Easom
Co-founder, President, and CEO
AN2 Therapeutics
Chair of the Board of Directors
Joseph S. Zakrzewski
Co-Founder, AN2 Therapeutics
Chair, Director
Kabeer Aziz
Principal, Adjuvant Capital
Director
Rob Readnour, PhD
Managing Director,
Mountain Group Partners
Director
Lynn Marks, MD
Senior Vice President (Retired),
GlaxoSmithKline
Director
Stephanie Wong
Chief Financial Officer, Calithera Biosciences
Director
Patricia Martin
President & CEO, Biocrossroads
Director
Melvin Spigelman, MD
GATB
Director
Maggie FitzPatrick
Fitzpatrick & Co, Founder & CEO
Lead Independent Director
Contact us
1300 El Camino Real
Suite 100
Menlo Park, CA 94025
General information:
info@an2therapeutics.com
Investor and media inquiries:
ir@an2therapeutics.com
Business development contact:
partner@an2therapeutics.com
Careers:
careers@an2therapeutics.com
Business development contact:
partner@an2therapeutics.com
Careers:
careers@an2therapeutics.com